Clinical efficacy of Huangkui capsules in the treatment of targeted drug-related proteinuria in patients with hepatocellular carcinoma
10.12025/j.issn.1008-6358.2025.20250544
- VernacularTitle:黄葵胶囊治疗肝癌靶向药物相关蛋白尿的临床疗效
- Author:
Miao LI
1
;
Jia YUAN
1
;
Chu LIU
2
;
Maopei CHEN
1
;
Xin XU
1
;
Ningling GE
1
;
Yi CHEN
1
;
Lan ZHANG
1
;
Rongxin CHEN
1
;
Yan WANG
1
Author Information
1. Department of International Therapy and Hepatobiliary Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
2. Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Publication Type:Shortarticle
- Keywords:
Huangkui capsule;
targeted therapy;
proteinuria;
hepatocellular carcinoma
- From:
Chinese Journal of Clinical Medicine
2026;33(1):88-94
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effect of Huangkui capsules on targeted drug-related proteinuria in patients with hepatocellular carcinoma (HCC). Methods A retrospective analysis was conducted on clinical data of HCC patients with targeted drug-related proteinuria from June 2023 to December 2024 at Zhongshan Hospital, Fudan University. According to the treatment plan, patients were divided into the conventional treatment group and the Huangkui combination treatment group (Huangkui capsules combined with conventional treatment), and the clinical efficacy between the two groups was compared. The logistic regression analysis was used to identify the main factors affecting treatment efficacy. Results The Huangkui combination treatment group (n＝29) showed a significantly higher overall effective rate (79.3% vs 42.3%, P＝0.005), and an earlier proteinuria improvement (median time: 3 months vs 6 months, P＝0.008) than the conventional treatment group (n＝26) . The multivariate logistic regression analysis showed angiotensin-converting enzyme inhibitor (ACEI) or angiotensin Ⅱ receptor blocker (ARB) using (OR＝0.190, 95%CI 0.045-0.808, P＝0.025), targeted drug adjustment (OR＝0.132, 95%CI 0.030-0.581, P＝0.007), and Huangkui capsules using (OR＝0.168, 95%CI 0.039-0.730, P＝0.017) were protective factors for treatment efficacy of targeted drug-related proteinuria. Conclusions On the basis of conventional treatment, additive treatment with Huangkui capsules can alleviate targeted drug-related proteinuria faster and more effectively in HCC patients.
